Cogent Biosciences, Inc.
bezuclastinib
Gastrointestinal Stromal Tumor
Resolved
38days ago
Phase 3 readout · May 30, 2026
What's at stake
Phase 3 trial results for bezuclastinib in Gastrointestinal Stromal Tumor are due May 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In November 2025, announced topline results from the Phase 3 PEAK trial of bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib, becoming the first positive Phase 3 trial in seco”